Showing posts with label serology. Show all posts
Showing posts with label serology. Show all posts

Saturday, June 6, 2026

Cross-reactive #Bundibugyo #antibody responses after licensed #Ebola #vaccines

 


Abstract

Background 

The ongoing Bundibugyo virus disease (BDBV) outbreak in Central Africa highlights the absence of approved vaccines specifically targeting BDBV. Whether licensed Zaire ebolavirus (EBOV) vaccines induce cross-reactive immunity against BDBV remains largely unknown.

Methods 

We performed an immunogenicity analysis using serum samples from participants enrolled in the PREVAC randomized clinical trial evaluating licensed Ebola vaccine strategies in West Africa. Samples collected at day 28 (D28) and month 3 (M3) following vaccination with rVSVΔG-ZEBOV-GP or Ad26.ZEBOV/MVA-BN-Filo were assessed using a multiplex Luminex assay against glycoproteins from multiple filoviruses, including EBOV Kikwit, EBOV Mayinga, BDBV, Sudan virus, Reston virus, and Marburg virus.

Results 

A total of 179 samples were analysed. Detectable cross-reactive antibody responses against BDBV were observed across vaccine groups, timepoints, and age categories. However, BDBV responses remained substantially lower than homologous EBOV responses. In rVSV recipients, median BDBV responses (net MFI) reached 282 (IQR 164–644) at D28 compared with 1788 (832–3311) against the homologous Kikwit antigen. Similar patterns were observed following rVSV booster vaccination and Ad26.ZEBOV/MVA-BN-Filo vaccination. The heterologous Ad26/MVA regimen demonstrated increasing BDBV responses between D28 and M3.

Conclusions 

Licensed EBOV vaccines induced detectable but quantitatively reduced cross-reactive antibody responses against BDBV. Although no direct assessment of vaccine efficacy against BDBV disease was possible, these findings support the plausibility of partial heterologous immunity following EBOV vaccination. In the absence of approved BDBV-specific vaccines, these data support the urgent evaluation of currently available Ebola vaccines during BDBV outbreaks and reinforce the importance of developing broadly protective pan-filovirus vaccines.


Competing Interest Statement

The authors have declared no competing interest.


Clinical Trial

NCT02876328

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.05.27.26354223v1

____

Wednesday, May 27, 2026

Detection of Anti- #H5 #Antibodies in People with Exposure to Wild #Birds in Northern #Canada

 


Abstract

Using a commercially available H5 serology assay, we identified a 7.4% (n=5/68) anti-H5 seroreactivity rate among hunters in Northern Canada. All participants reported close contact with wild birds.


Competing Interest Statement

This study was performed outside of JK's duties and responsibilities with the Public Health Agency of Canada.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.05.24.26353994v1

____

Thursday, May 21, 2026

#Coronavirus #diversity and #SARS-CoV-2 #exposure at the #wildlife – #human interface in Northern #Italy

 


Abstract

Background

Members of the Coronaviridae family infect humans as well as domestic and wild animals. Over the past three decades, three members of this family, all with zoonotic origins, have caused significant epidemics or pandemics (SARS, MERS, and COVID-19). Despite the spread of SARS-CoV-2 being primarily driven by human-to-human transmission, various animal species are susceptible to infection and may contribute to viral circulation. Aim of this work was to monitor coronavirus (CoV) infections in wild mammals in the Emilia-Romagna region (RER), Italy, using a combined approach of molecular screening for viral RNA detection and serological testing for anti-SARS-CoV-2 antibodies.


Methods

Respiratory and gastrointestinal tissue samples were collected from wild animal carcasses between 2022 and 2024. Samples were tested for SARS-CoV-2 using two RT-qPCR assays targeting the E and N genes, and for other CoVs using a nested pan-coronavirus RT-PCR followed by Sanger sequencing of positive samples. Additionally, serum samples obtained from blood, cardiac clot, or thoracic exudate were screened for antibodies against the SARS-CoV-2 nucleocapsid (N) protein, with positive samples subsequently confirmed by an ELISA targeting antibodies to the receptor-binding domain (RBD) of the Spike (S) protein, focused on variants circulating during the study period.


Results

Molecular analyses were performed on 2,238 animals, all of which tested negative for SARS-CoV-2, while 90 (79% hedgehogs) tested positive for CoVs. Among these, most sequences were consistent with coronaviruses typically reported in the respective host species. However, some exceptions – such as Betacoronavirus erinacei in fox, porcupine, hare, and roe deer, and EmbeCoV-related sequences in a porcupine – warrant further attention. Suitable serum samples were available from 1,751 animals. Overall, 65 animals tested positive for anti-N antibodies, 31 of which (22 foxes, 4 badgers, 2 hedgehogs, 1 roe deer, 1 wolf, 1 rat) were subsequently confirmed by an anti-RBD ELISA.


Conclusions

This study provides an overview of CoVs circulation among wild mammals in RER, supporting the role of hedgehogs as reservoirs and identifying some species with evidence of exposure to SARS-CoV-2. Certain unexpected findings highlight the need for further investigations to clarify the potential for cross-species transmission.

Source: 


Link: https://link.springer.com/article/10.1186/s12985-026-03193-3

____

Wednesday, May 13, 2026

Pre-existing systemic and #nasal #antibodies against avian #H5 #influenza A viruses vary according to #childhood imprinting

 


Abstract

Avian influenza A viruses (IAV) pose a constant pandemic threat, with the recent 2.3.4.4b clade of the H5 subtype causing high pathogenicity and spreading across animal species and geographic locations. Understanding human pre-existing immunity to avian H5 IAV can inform on population susceptibility, a critical aspect of pandemic preparedness. To that end, we analysed the IAV HA-specific antibodies across individuals born between 1928-1999 with different early life exposures to IAV subtypes. Individuals born prior to 1957 had the highest pre-existing serum antibodies to group 1 HA antigens, including the 2.3.4.4b H5 and a group 1 HA stem antigen. These birth-year-specific patterns were not reflected in the limited pre-existing serum neutralising antibodies detectable against a 2.3.4.4b H5 IAV or in H5-specific memory B cell populations. They were however evident in pre-existing nasal IgG and IgA titres to H5, which were greater in individuals born prior to 1957. Our findings demonstrate that the immunological biases afforded by early life exposure extend to antibodies detected in the nasal mucosa, the site of IAV replication.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.08.723737v1

____

Tuesday, May 12, 2026

Cross-reactive #human #antibody responses to #H5N1 #influenza virus #neuraminidase are shaped by immune history

 


Abstract

H5N1 highly pathogenic avian influenza viruses have spread globally and pose a pandemic risk. Prior studies suggest that early life exposures to group 1 influenza viruses (H1N1 and H2N2) prime antibodies that cross-react to the hemagglutinin of H5N1, which is also a group 1 virus. However, less is known about how immune history affects antibody responses against the H5N1 neuraminidase (NA). We measured NA inhibition antibodies against multiple H5N1 viruses using sera from 155 individuals born between 1927 and 2016. Individuals likely primed in childhood with H1N1 viruses possessed higher levels of antibodies that cross-react with the NA of H5N1 viruses compared to those primed with H2N2 or H3N2 viruses. While young children rarely possessed cross-reactive N1 antibodies, childhood infections with contemporary H1N1, but not H3N2, viruses elicited them. We also measured antibodies against an H5N5 virus (A6 genotype) that recently caused a fatal infection in the United States. Consistent with the lack of circulation of N5 viruses in humans, we found low levels of antibodies against the N5 NA. Our data suggest that immune history greatly impacts the generation of cross-reactive NA antibodies, and that reassortment with other NAs may increase the risk of H5 infection of humans.

Source: 


Link: https://www.nature.com/articles/s41467-026-72941-4

____

Saturday, May 9, 2026

#Genetic and #biological characterization of #H9N2 avian #influenza viruses isolated from #swine in #China

 


Abstract

Background

H9N2 avian influenza virus (AIV) has been circulating in poultry in China for decades and are undergoing adaptation to mammals, posing potential pandemic risks. To investigate the prevalence of H9N2 AIVs in swine, we conducted surveillance in Shandong Province from 2021 to 2023.

Results

Two H9N2 influenza virus strains, A/swine/Shandong/417/2021(Sw/SD/417/21) and A/swine/Shandong/662/2022 (Sw/SD/662/22), were successfully isolated from swine and genetically characterized. Phylogenetic analyses showed that both isolates were reassortants containing gene segments from multiple H9N2 AIV lineages and closely related to currently circulating H9N2 AIV. Key molecular marker analysis revealed that both isolates carried mammalian-adaptive residues in the HA receptor-binding sites (183 N, 190 V, 226 L), a novel HA cleavage site variant (PSKSSRGL), PB2 mutations (A588V, E627V), and the M2 S31N substitution, suggesting potential adaptation to mammalian hosts and resistance to adamantane antivirals. Mice infection experiments demonstrated efficient viral replication in the respiratory tract, particularly in the lungs, but only mild histopathological changes were observed, with no significant weight loss or mortality, indicating low pathogenicity in mice. Serological surveillance of 3,172 swine serum samples showed a low prevalence of H9N2 influenza virus infection (0.44%), with positive samples sporadically distributed across regions and years.

Conclusion

In summary, although H9N2 AIV infection in swine is rare and generally mild, the presence of mammalian-adaptive markers and reassortant genomes highlights the potential risk of cross-species transmission and subclinical adaptation. Continuous avian–swine–human influenza surveillance is therefore essential to mitigate the potential threat posed by H9N2 AIV.

Source: 


Link: https://link.springer.com/article/10.1186/s12917-026-05501-z

____

Thursday, May 7, 2026

Serologic #Evidence of #Influenza #H5N1 Virus #Infection in a #Veterinary Professional Exposed to an Infected #Cat — Los Angeles County, #California, Dec. '24–Jan. '25

 


Summary

-- What is already known about this topic?

- Transmission of influenza A(H5N1) viruses from domestic cats to humans has not been documented.

-- What is added by this report?

- During November 2024–January 2025, a total of 139 persons exposed to 19 A(H5N1)-infected domestic cats that consumed raw animal products were identified in Los Angeles County, California. Among 25 exposed persons who received serologic testing, one asymptomatic veterinary professional had serologic evidence of A(H5N1) infection after occupational exposure to an A(H5N1)-infected cat.

-- What are the implications for public health practice?

- These findings provide evidence of zoonotic transmission of influenza A(H5N1) virus from domestic cats to humans. Pet owners are advised not to feed raw animal products to cats. Veterinary professionals should be aware of infection risks, use appropriate personal protective equipment, and adhere to recommended infection control practices to reduce the risk for zoonotic transmission of influenza A(H5N1).


Abstract

Since 2021, avian influenza A(H5N1) clade 2.3.4.4b viruses have spread widely among wild birds and domesticated poultry in the United States, with sporadic spillover into mammals. During November 2024–January 2025, 19 domestic cats in Los Angeles County, California, became ill after consumption of commercially purchased raw milk, raw meat, or raw pet food; nine cats tested positive for influenza A(H5N1) virus (clade 2.3.4.4b genotype B3.13). Overall, 139 persons were exposed to the 19 infected cats, and all were monitored for symptoms. Although 30 persons reported influenza-like illness symptoms, none received a positive influenza A(H5) reverse transcription–polymerase chain reaction (RT-PCR) test result. In April 2025, the Los Angeles County Department of Public Health and CDC invited all exposed persons to participate in an influenza A(H5N1) serosurvey to determine whether transmission of influenza A(H5N1) virus occurred, including in those without symptoms. Sera from 25 (18%) of the 139 exposed persons were tested. Among these, antibodies specific to A(H5N1) clade 2.3.4.4.b (antigenically similar to the clade 2.3.4.4.b influenza A[H5N1] virus isolated from the infected cats) were detected in serum from one veterinary professional, who was asymptomatic. This person did not use respiratory or eye protection during the exposure, did not report influenza-like illness after the exposure, and reported no other known risk factors for A(H5N1) infection. These findings represent serologic evidence of possible transmission of influenza A(H5N1) clade 2.3.4.4.b virus from a domestic cat to a human, highlighting concerns about potential cat-to-human transmission of influenza A(H5N1) virus and the importance of infection control practices in veterinary settings.

Source: 


Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7517a1.htm?s_cid=OS_mm7517a1_e&ACSTrackingID=USCDC_921-DM155047&ACSTrackingLabel=Week%20in%20MMWR%3A%20Vol.%2075%2C%20May%207%2C%202026&deliveryName=USCDC_921-DM155047

____

Tuesday, May 5, 2026

#Surveillance on #California dairy #farms reveals multiple possible sources of #H5N1 #influenza virus #transmission

 


Abstract

Transmission routes of highly pathogenic H5N1 between cows or to humans remain unclear due to limited data from affected dairy farms. We performed air, farm wastewater, and milk sampling on 14 H5N1-positive dairy farms across two different California regions. Infectious virus was detected in the air in milking parlors and in wastewater streams, while viral RNA was found in exhaled breath of cows. Sequence analysis of infectious H5N1 virus from air and wastewater samples on one farm revealed viral variants relevant for potential human susceptibility. Longitudinal analysis of milk from the individual quarters of cows revealed a high prevalence of subclinical H5N1-positive cows. Additionally, a heterogeneous distribution of infected quarters that maintained a consistent pattern over time was observed, inconsistent with shared milking equipment serving as the sole transmission mode. The presence of subclinically infected cows was further supported by detection of antibodies in the milk of animals that exhibited no clinical signs during the H5N1 outbreak on one farm. Our data highlight additional sources and potential modes of H5N1 transmission on dairy farms.

Source: 


Link: https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003761

____

Thursday, April 30, 2026

#Orthopoxvirus #Antibodies in Feral #Mammals in #Mpox #Outbreak Areas, #Nigeria, 2021–2022

 


Abstract

We analyzed tissue and serum samples from 124 wild animals from communities with confirmed mpox cases in Nigeria. Tissue samples were PCR-negative, but serum samples from 8 animals (6.45%)—3 feral cats, 4 giant pouched rats, and 1 shrew—revealed Orthopoxvirus antibodies, suggesting these species as probable reservoirs.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/5/25-1565_article

____

Tuesday, April 28, 2026

Serologic #Surveillance of Highly Pathogenic Avian #Influenza Virus Subtype #H5 in #Wildlife, Northeast #Germany, 2023–2025

 


Abstract

We tested wild ruminants, boar, and carnivores in northeast Germany for highly pathogenic avian influenza subtype H5 antibodies. Wild ruminants were seronegative, but 3.5% of boar and 12.5%–21.9% of carnivores were seropositive, indicating frequent spillover. Because such events might accelerate mammalian (and ultimately human) adaptation, sustained monitoring remains essential.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/5/25-1555_article

____

Sunday, April 19, 2026

#Ocular findings in Northern #Gannets following an #outbreak of high pathogenicity avian #influenza #H5N1

 


Abstract

During 2021-2022, high pathogenicity avian influenza (HPAI) caused mass mortality in wild birds across Europe, with Northern Gannets (Morus bassanus) among the most affected. Following the outbreak, unusual alterations in the species' characteristic pale iris were observed in some individuals. Opportunistically captured gannets on Bass Rock (n=52), selected to represent a range of iris pigmentation, were examined. Slit-lamp biomicroscopy, indirect ophthalmoscopy, rebound tonometry and photography were performed. Iris pigmentation was classified as normal, mottled or black. Eleven birds underwent avian influenza virus (AIV) serology. Histopathology was performed on two eyes. Abnormal iris pigmentation was found in 74% of adult and immature gannets, with 61% affected bilaterally. Additional signs consistent with uveitis were present in 77% of affected birds. Iris pigmentation abnormalities were positively associated with AIV H5 seropositivity (Fishers exact test, P=0.018). Histopathology from affected eyes showed increased melanin deposition and disorganisation, including loss of a distinct anterior layer of melanocytic cells and hypertrophy of melanocytes within the iris stroma. Field conditions limited uniform lighting and concurrent serology. Iris pigmentation changes were associated with prior HPAI exposure and frequently accompanied by signs of uveitis, suggesting iris alterations may indicate past infection and potential chronic sequelae.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.04.15.718625v1

____

Thursday, April 16, 2026

#SARS-CoV-2 #vaccination and #infection elicit cross-neutralizing responses against clade 3 and 4 #sarbecoviruses

 


Abstract

Two sarbecoviruses, SARS-CoV-1 and SARS-CoV-2 that engage ACE2 through their receptor-binding domains, have caused major human outbreaks. The pandemic potential of sarbecoviruses has prompted the discovery and classification of bat and other zoonotic sarbecoviruses that are also able to use human ACE2 or ACE2 ortholog receptors for infection. However, the current human immunological landscape reactive to these SARS-CoV-2-related viruses is not well profiled. Using a panel of pseudotyped lentiviruses expressing only spike proteins, we assess serum neutralization activity against clade 3 and 4 (also designated as clade 1c) receptor binding domain classified sarbecoviruses in a cohort who received a primary series of COVID-19 mRNA vaccines as well as individuals before and after infection with BA.5 or XBB.1.5 variants. Detectable neutralizing responses against clade 3 and 4 sarbecoviruses are observed in both vaccinees and convalescents and are comparable in magnitude to titers against SARS-CoV-2 variants. Infection with XBB.1.5 increases neutralization titers against SARS-CoV-2 variants as well as against clade 3 and 4 sarbecoviruses. Collectively, our findings suggest that the current immunologic landscape of vaccination and infection may confer some level of immunity against a variety of clade 3 and 4 sarbecoviruses, which should inform future pandemic response and pan-sarbecovirus countermeasure efforts.

Source: 


Link: https://www.nature.com/articles/s41467-026-71662-y

____

Monday, April 13, 2026

#Population #immunity to clade 2.3.4.4b #H5N1 is dominated by anti - #neuraminidase #antibodies

 


ABSTRACT

Clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses continue to expand geographically and across mammalian hosts, raising concern about pandemic potential. The degree and specificity of pre-existing immunity in humans are key determinants of this risk. We analyzed hemagglutinin (HA)- and neuraminidase (NA)-specific antibody responses in 300 sera collected from adults in New York City. While HA directed binding antibodies to clade 2.3.4.4b H5 were low and hemagglutination-inhibiting antibodies were absent, we detected widespread binding and functional NA antibodies against N1 neuraminidases from clade 2.3.4.4b H5N1 viruses. Neuraminidase inhibition (NI) titers were highest against North American D1.1 genotype N1 viruses and correlated strongly with neutralizing activity, whereas HA-binding antibodies did not. An additional N-linked glycosylation site, as found in the NA of a human D1.1 isolate from British Columbia, reduced susceptibility to NI antibodies. Antibodies titer to N5 from H5N5 were low to minimal. These findings indicate that population-level immunity to clade 2.3.4.4b H5 viruses is dominated by NA-directed antibodies, with important implications for pandemic risk assessment.


IMPORTANCE

Understanding how pre-existing human immunity shapes susceptibility to emerging influenza viruses is central to pandemic preparedness. Here, we determined that human sera contain widespread, functional antibodies targeting H5N1 neuraminidase, which correlate with virus neutralization, whereas HA-directed responses are limited. We further show that acquisition of an NA glycosylation site reduces antibody inhibition, highlighting a potential pathway for immune evasion. These results identify neuraminidase-specific immunity as a major immunological barrier to severe H5N1 disease in humans and emphasize the need to incorporate NA antigenicity into influenza surveillance, risk assessment, and next-generation vaccine design.

Source: 


Link: https://journals.asm.org/doi/10.1128/mbio.00445-26

____

Thursday, April 9, 2026

#Birth #imprinting effects on the #antibody responses of #H7N9 patients from 2013-2018 in #China

 


Abstract

Background

There is an urgent need to understand the immune correlates of protection against avian influenza viruses (AIV), where pre-existing immunity may be limited.

Methods

Here, we characterized the antibody response in 12 severely ill A(H7N9) patients and examined its association with early-life imprinting and clinical outcome.

Results

We find that A(H7N9) patients imprinted with A(H2N2) during early life show minimal H7-IgM and a rapid IgG response across diverse hemagglutinin subtypes. They also have more high avidity H7-antibodies compared to older or younger patients. Early antibody titers against seasonal H1, H3, and conserved stalk domains trend negatively with clinical severity in A(H7N9) infection, while an inverse pattern is observed following severe A(H1N1) infection, potentially suggesting a different mechanism of immune regulation between seasonal and avian influenza virus infections.

Conclusions

These data provide direct serological evidence that birth imprinting profoundly shapes the humoral immune landscape during zoonotic influenza infection and may influence subsequent disease outcome.

Source: 


Link: https://www.nature.com/articles/s43856-026-01554-1

____

Tuesday, March 3, 2026

#MERS #Coronavirus–Specific T-Cell Responses in Dromedary #Camel #Abattoir #Workers in #Nigeria Suggests Frequent Zoonotic #Spillover

 


Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is assessed to have high pandemic risk, and dromedary camels are the source of zoonotic spillover. More than 75% of MERS-CoV–infected dromedary camels are found in Africa, but no zoonotic disease has been reported from Africa where there is little awareness of MERS-CoV as a potential cause of respiratory disease. Antibody responses are a poor indicator of mild infection. We found that 47 of 60 (78%) dromedary camel abattoir workers in Kano, Nigeria, had MERS-CoV–specific T-cell responses while none of 18 controls did, suggesting that zoonotic infection is common in camel-exposed individuals in Africa.

Source: 


Link: https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiag095/8504072?redirectedFrom=fulltext

____

Friday, February 13, 2026

Population #immunity to clade 2.3.4.4b #H5N1 is dominated by anti-neuraminidase #antibodies

 


Abstract

Clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses continue to expand geographically and across mammalian hosts, raising concern about pandemic potential. The degree and specificity of pre-existing immunity in humans are key determinants of this risk. We analyzed hemagglutinin (HA)- and neuraminidase (NA)-specific antibody responses in 300 sera collected from adults in New York City. While HA directed binding antibodies to clade 2.3.4.4b H5 were low and hemagglutination-inhibiting antibodies were absent, we detected widespread binding and functional NA antibodies against N1 neuraminidases from clade 2.3.4.4b H5N1 viruses. Neuraminidase inhibition (NI) titers were highest against North American D1.1 genotype N1 viruses and correlated strongly with neutralizing activity, whereas HA-binding antibodies did not. An additional N-linked glycosylation site, as found in the NA of a human D1.1 isolate from British Columbia, reduced susceptibility to NI antibodies. Antibodies to N5 from H5N5 were minimal. These findings indicate that population-level immunity to clade 2.3.4.4b H5 viruses is dominated by NA-directed antibodies, with important implications for pandemic risk assessment.


Competing Interest Statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list FK as co-inventor and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. VS is listed on the patent for the SARS-CoV-2 serological assay. FK is co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Sanofi, Gritstone, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development.


Funding Statement

This work was funded through the NIAID Centers for Excellence in Influenza Research and Response (75N93021C00014 as well as option APOLLO Option 12A) and through philanthropic support from Titos Vodka. Work at the Medical University of Vienna was funded by Institutional Funds.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.02.10.26346014v1

____

Thursday, January 22, 2026

Detection of Avian #Influenza #H5–Specific #Antibodies by Chemiluminescent Assays

 


Abstract

We evaluated 2 electrochemiluminescence serologic assays to detect avian influenza H5 antibodies. Both assays identified H5 antibodies from both serum and dried blood spots and had strong specificity and minimal cross-reactivity in human and avian samples. Such assays can support populationwide serologic surveys aimed at assessing population-level immunity.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/1/25-1117_article

____

Monday, January 5, 2026

Development of a multi-species #luciferase-based double #antigen #ELISA for the detection of #antibodies against #Influenza A virus #H5 clade 2.3.4.4b

 


Abstract

The highly pathogenic avian influenza viruses (HPAIV) of subtype H5N1 represent a major threat to animal and public health. The current panzootic with H5 clade 2.3.4.4b has caused numerous, widespread outbreaks in various domestic and wild avian species with high mortalities, massive losses and a high frequency of spillover events to unexpected novel mammalian hosts such as dairy cows. The global H5N1 situation raises serious concerns about zoonotic risks due to effective mammal-to-mammal transmission. Therefore, it is critical to increase surveillance intensity of a broadened species range, particularly at the human-animal interface. For this purpose, reliable and cost-effective serological tools that are easy to perform and suitable for high-throughput screenings are critically needed. The newly developed double antigen ELISA format employing a luminescence-based detection technology has demonstrated to comply with such prerequisites. The assay allowed the detection of H5-specific antibodies even early after infection or vaccination in a wide range of birds and mammals including humans. It further demonstrated superior analytical sensitivity and high specificity for antibodies directed against H5 hemagglutinin of clade 2.3.4.4b as no cross-reactivity with other hemagglutinin subtypes was observed. Thus, the assay represents a valuable contribution to existing serological diagnostic tests for a clade-optimized detection of influenza A virus antibodies in a broad range of species.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.01.05.697617v1

____

Sunday, December 21, 2025

#Serological evidence of concurrent #Lassa virus and #SARS-CoV-2 #exposure in #Ghana- a cross-sectional study

 


Abstract

Background

The COVID-19 pandemic has exposed vulnerabilities in infectious disease surveillance, especially in West Africa where endemic viruses including Lassa fever persist. The overlapping clinical symptoms of these two infections create diagnostic challenges and the possibility of undetected co-infections.

Methods

A retrospective cross-sectional study was conducted using archived serum samples from a nationwide SARS-CoV-2 seroprevalence survey in Ghana. 434 samples across six regions were tested for SARS-CoV-2 total antibodies (IgG/IgM) using the WANTAI ELISA kit and Lassa virus IgG using ReLASV Pan-Lassa-NP-IgG ELISA.

Results

SARS-CoV-2 antibody prevalence was 64.29% (n = 279) and Lassa virus IgG prevalence was 20.28% (n = 88). Of the cohort of subjects who were seropositive for SARS-CoV-2, 20.79% were also seropositive for LASV IgG. Multivariate analysis revealed household size as a strong risk factor of dual exposure. Individuals from medium-sized households (4–6 persons) (aOR = 8.78, 95% CI: 1.18–65.56, p = 0.034) and large households (≥ 7 persons) (aOR = 12.90, 95% CI: 1.99–83.40, p = 0.007) had significantly increased odds of dual seropositivity compared to small households. Regional variations were observed, with Greater Accra showing significantly lower odds of dual seropositivity (aOR = 0.13, 95% CI: 0.03–0.51, p = 0.004) compared to Ashanti Region.

Conclusion

This study provides serological evidence of SARS-CoV-2 and Lassa virus concurrent exposure in Ghana during the COVID-19 pandemic. This finding suggests large household size as a key driver of dual viral exposure and calls for integrated surveillance systems and targeted interventions in large household settings to reduce concurrent transmission of viruses with pandemic potential.

Source: 


Link: https://link.springer.com/article/10.1186/s12879-025-12385-1

____

Tuesday, December 9, 2025

Pre-existing cross-reactive #immunity to highly pathogenic avian #influenza 2.3.4.4b #H5N1 virus in the #USA

 


Abstract

The unprecedented 2.3.4.4b. A(H5N1) outbreak in dairy cattle, poultry, and spillover to humans in the United States (US) poses a major public health threat. Population immunity is a critical component of influenza pandemic risk assessment. We assessed the pre-existing cross-reactive immunity to 2.3.4.4b A(H5N1) viruses and analyzed 1794 sera from 723 people (0.5–88 yrs) in multiple US geographic regions during 2021–2024. Pre-existing neutralizing and hemagglutinin (HA)-head-binding antibodies to A(H5N1) were low, but there were substantial cross-reactive binding antibodies to N1 neuraminidase (NA) of 2.3.4.4b A(H5N1). Antibodies to group 1 HA stalk were also prevalent and increased with age. A(H1N1)pdm09 infection and influenza vaccination did not induce neutralizing antibodies to A(H5N1) viruses but induced significant rise of functional NA inhibition (NAI) antibodies to N1 of 2.3.4.4b A(H5N1), and group 1 HA stalk antibodies. Moreover, pre-pandemic stockpiled 2.3.4.4c vaccine can elicit cross-reactive neutralizing antibodies to 2.3.4.4b A(H5N1) viruses. Understanding population susceptibility is essential for pandemic preparedness.

Source: 


Link: https://www.nature.com/articles/s41467-025-66431-2

____

My New Space

Most Popular Posts